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Naturally-derived macrocyclic compounds are associated with a diverse range of biological activities,
including antibacterial effects, and there are over 100 marketed macrocycle drugs derived from natural
products. However, synthetic macrocycles are widely considered to be poorly explored in antibiotic
development (indeed, within drug discovery in general). This has been attributed to challenges associ-
ated with the generation of such compounds. Whilst there are synthetic methods that can produce large
collections of structurally similar macrocycles (i.e., compounds with varying appendages based around
similar core macrocyclic ring architectures) there is a relative dearth of strategies for the efﬁcient gen-
eration of more structurally diverse macrocycle collections in which there is greater variation in the
nature of macrocyclic scaffolds present. Such macrocycle collections should contain compounds with
a broad range of biological activities (including antibacterial activities) and the requisite robust synthetic
methodology useful for analogue synthesis and lead optimization once an active compound has been
identiﬁed in a biological screen. Herein, we describe a new and expedient diversity-oriented synthesis
(DOS) strategy for the generation of a library of novel structurally diverse macrocyclic compounds with
a high level of scaffold diversity. The strategy is concise, proceeds from readily-available starting ma-
terials, is modular in nature and features a variety of macrocyclisation techniques. In this proof-of-
concept study, the synthesis of several previously unreported macrocyclic compounds was achieved.
Each of these macrocycles was based around a distinct molecular scaffold and contained natural product-
like structural features (e.g., three-dimensionality and multiple hydrogen bond donors and acceptors) as
well as synthetic handles for potential further elaboration. The successful generation of these macro-
cycles demonstrates the feasibility of the new DOS strategy as a synthetic platform for library generation.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The inexorable rise in antibiotic-resistant bacteria has led to
a steady decline in the efﬁcacy of existing therapies for the treat-
ment of bacterial infections.1,2 Moreover, the pace at which new
antibacterial agents are being generated has decreased dramati-
cally in recent decades, a legacy of insufﬁcient investment in fun-
damental antibacterial research by pharmaceutical companies
since the 1960s.1,2 Consequently, humanity is facing the very real
and disturbing possibility of a future without an effective method
for the treatment of some common bacterial infections.1,2 Thus,
there is a clear and critical medical need for the discovery of novel
antibiotics.1,3; e-mail address: spring@ch.
r Ltd. This is an open access articlLead compounds for antibacterial chemotherapy can be ob-
tained from two sources: nature (natural products) or de novo
chemical synthesis.1 Historically, nature has been by far the more
important; most of the major classes of antibiotics in therapeutic
use are natural products or semi-synthetic derivatives thereof.1,3
Among these, a macrocyclic scaffold (a ring system of 12 or more
atoms) is common (Fig. 1). Indeed, naturally-derived macrocycles
constitute a large class of compounds with useful antibacterial
properties.4e6 Natural macrocyclic derivatives are also associated
with a broad range of other attractive biological effects (including
anticancer, antifungal and immunosuppressive activities)5,7 and
there are more than 100 marketed macrocyle drugs derived from
natural products.8 The diverse and interesting biological activities
associated with the macrocyclic compound class has been attrib-
uted to characteristic structural features.7,8 Their cyclic structure
means that they have less conformational freedom than an equiv-
alent acylic compound and so suffer a smaller entropic loss upone under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Some examples of naturally-derived antibiotics which are based around mac-
rocyclic scaffolds (highlighted in bold). Erythromycin A (1) and Fidaxomicin (3) are
natural products and Azithromycin (2) is a semi-synthetic compound.5
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systems, macrocycles retain a certain ﬂexibility, allowing them to
potentially mould to a target surface in order to maximize binding
interactions.7e9 In addition, macrocycles can potentially adopt
conformations in which polar motifs are buried away, leading to
improved membrane permeability relative to their linear
analogues.7
Clearly, macrocycles represent attractive targets in the search
for new lead compounds for antibiotic development (indeed, drug
development in general).4,7,8 However, naturally occurring macro-
cycles are often highly complex in structure, which hampers their
synthetic modiﬁcation and pharmacokinetic optimization.4,7,10
Thus, attention has shifted in recent years towards the explora-
tion of synthetic macrocycles of medium complexity in drug dis-
covery.7,10 There has been notable success in this ﬁeld, with many
biologically active synthetic macrocycles with appropriate phar-
macokinetic proﬁles identiﬁed10 (including antibacterial lead
compounds11,12). However, despite these encouraging examples,
synthetic macrocycles are still widely considered to be relatively
underexplored within drug discovery in general.7e10,13 This has
been attributed to challenges associated with the synthesis of such
compounds, particularly in the context of the formation of the
macrocyclic ring architecture.7,9Where present in a small molecule,
the macrocyclic ring is generally considered to serve as the mo-
lecular scaffold (i.e., the core rigidifying structural feature of
a molecule).14 Whilst there are synthetic methods that can produce
large collections of structurally similar macrocycles (i.e., com-
pounds with varying appendages based around similar core mac-
rocyclic scaffolds) there is a relative dearth of strategies for the
efﬁcient generation of more structurally diverse macrocycle col-
lections in which there is greater variation in the nature of mac-
rocyclic scaffolds present.10,14 This is a crucial issue in the context of
biological screening, since the overall structural, and thus func-
tional diversity of a compound set (i.e., the range of biological ac-
tivities displayed by the compounds) is known to be highly
dependent upon the variety of molecular scaffolds present (the
scaffold diversity) of the collection.15e17 Macrocyclic collectionswith higher levels of scaffold diversity would be expected to pro-
vide a higher hit rate against a broader range of targets than li-
braries with lower scaffold, and thus overall structural,
diversity.14,15 Scaffold diverse macrocycle collections would there-
fore be expected to be particularly valuable in biological screens
where the nature of the biological target is unknown (e.g., in
phenotypic screening).15,18 In addition, efﬁcient access to structur-
ally diverse macrocycles necessitates the development of synthetic
methodology which is robust and broadly applicable in nature,
which should facilitate the lead optimization process once a hit
compound has been identiﬁed.11,19
Diversity-oriented synthesis (DOS) is a ﬁeld of organic chemis-
try directed towards the efﬁcient generation of molecular libraries
that incorporate high degrees of structural diversity, including
scaffold diversity.15,20e22 The screening of DOS libraries has led to
the identiﬁcation of numerous novel biologically active small
molecules, including several with antibacterial activities.3,15,23e28
Recent years have seen the development of several DOS-type
strategies speciﬁcally targeted at macrocyclic structures including
examples from our own research group.9,10,14,19,27,29e33 However,
there remains considerable scope for further developments in the
ﬁeld. From a synthesis perspective, there are improvements that
can be made in terms of the expediency of library construction and
the efﬁciency inwhich scaffold diversity is generated.19 In addition,
large areas of macrocyclic chemical space, that may contain mole-
cules with exciting biological properties (e.g., critically needed new
antibacterials), still remain under-explored. These considerations
highlight the need for new and expedient DOS strategies towards
previously undescribed macrocyclic compounds. Herein, we de-
scribework towards the development of one such strategy, which is
based around the use of readily-accessible phenolic carbonyls as
key starting materials. In a proof-of-concept study the synthesis of
several structurally diverse and previously unreported macrocyclic
scaffolds was achieved, which provides a validation of this DOS
strategy as a synthetic platform for library generation.
2. Results and discussion
2.1. Outline of the synthetic strategy
Many DOS pathways are based around a three-phase build/
couple/pair (B/C/P) algorithm.20 In the build phase, starting mate-
rials (or building blocks) are synthesized. These are then combined
(coupled together) in the couple phase to yield densely function-
alized substrates for the subsequent pair phase, which involves
intramolecular reactions that join pairwise combinations of func-
tional groups to generate distinct molecular scaffolds.14,20 In recent
years, the use of iterative couple steps (i.e., B/C/C/P, B/C/C/C/P, etc.)
has been exploited as a means to increase the diversity of scaffolds
accessible from a given set of building blocks.14,34 For example, we
have recently reported a DOS strategy towards macrocyclic pepti-
domimetic scaffolds that incorporates iterative couple steps.14 It
was thought that the iterative couple concept could be used as the
basis for a new and expedient DOS strategy towards novel and di-
verse macrocyclic compounds. We conceived the use of readily-
accessible phenolic compounds of the general form 4, which bear
an electrophilic carbonyl group and a nucleophilic hydroxyl group,
as key starting materials (Scheme 1). It was hoped that each given
aromatic compound would serve as a ‘platform’ onto which dif-
ferent building blocks (generated in the build phase of the DOS)
could be attached through functionalisation of these two reactive
sites (couple stages). This would then afford a range of distinct
acyclic precursors, which could then undergo intramolecular re-
actions to furnish different macrocyclic compounds, each based
around a distinctmolecular scaffold (pair phases). More speciﬁcally,
we envisaged the use of four general types of building blocks: the
Scheme 1. Outline of the DOS strategy towards structurally diverse macrocyclic compounds of the general forms 14e16. The shaded shapes represent scaffold-deﬁning elements
(i.e., regions that can be varied to obtain different macrocyclic scaffolds). LG¼a leaving group (e.g., a halogen).
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would contain an aldehyde or a carboxylic acid moiety together
with the hydroxyl group), together with ‘hydroxyl capping’ build-
ing blocks 5 and 6 ‘carbonyl capping’ building blocks 7 and 8 (cyclic
and acyclic amines in both cases) and malonic acid (9), a ‘spacer’
building block. It was anticipated that the ‘platform’ aromatic
building blocks 4 could be functionalised at the hydroxyl position (a
couple phase) by reaction with the appropriate ‘hydroxyl capping’
building block 5 or 6 to furnish compounds of the general form 10
and 11 (from aromatic carboxylic acids and aromatic aldehydes,
respectively, Scheme 1). Subsequent functionalisation of the car-
bonyl moieties with the appropriate ‘carbonyl capping’ building
block 7 or 8 (a couple phase) would generate compounds of the
general form 12 (by amide bond formation from 10) and 13 (by
reductive amination from 11). Compounds of the form 12 and 13
contain functional groups that could then potentially be reacted
together intramolecularly in the subsequent pair phase of the DOS
to access diverse macrocyclic scaffolds (B/C/C/P pathways).Speciﬁcally, compounds 12 contain a terminal alkyne and terminal
azide group; it was envisaged that a regioselective metal-catalysed
‘click’-type 1,3-dipolar cycloaddition would thus furnish macrocy-
clic architectures of the general form 14 containing either 1,5-
disubstituted triazoles (ruthenium catalysis) or 1,4-disubstituted
triazoles (copper catalysis).
In the case of compounds 13, which contain two terminal alkene
moieties, it was hoped that an intramolecular ring-closing me-
tathesis reaction could be carried out to yield macrocyclic scaffolds
of the general form 15. Furthermore, it was envisaged that larger-
sized macrocyclic structures 16 could be accessed by extension of
the aldehyde moiety of key branchepoint compounds 11 by an
additional couple step with the ‘spacer’ building block 9 (a Knoe-
venagel condensation) to form compounds 17. Subsequent carbonyl
capping with building blocks 8 would generate compounds 18
which contain a terminal alkene and a terminal alkyne. Ring-
closing ene-yne metathesis would then furnish the target com-
pounds 16 (the pair stage). This would formally constitute a B/C/C/
J.J. Ciardiello et al. / Tetrahedron 72 (2016) 3567e35783570C/P pathway. These larger-sized macrocycles may be better able to
target extended binding interfaces (such as those associated with
proteineprotein interactions) than the smaller-sized compounds
resulting from a single couple step.14,35 Overall, we anticipated that
the DOS strategy outlined in Scheme 1 would allow access to novel
and structurally diverse macrocyclic compounds of three different
structural forms 14e16. Several attractive features of the proposed
DOS strategy were identiﬁed. It is step-efﬁcient from readily
available building blocks. Furthermore, it is inherently modular in
nature. Thus, it was anticipated that high levels of structural di-
versity could be achieved in an expedient fashion through the use
of a small set of building-blocks. Variation in the scaffold-deﬁning
elements of the building blocks should allow for efﬁcient genera-
tion of scaffold diversity within each general structural form, as
well as providing scope for the installation of diverse achiral and
chiral appendages and potential biomolecular-interacting elements
around the core macrocyclic ring architectures. The use of different
macrocyclisation techniques in the DOS should also offer an ex-
pansion in the number of distinct molecular scaffolds accessible
from a given set of building blocks (relative to strategies which
employ only one method of ring-closure). Furthermore each
method of macrocyclisation should furnish product scaffolds con-
taining different characteristic structural motifs. In the case of ring-
closure by 1,3-dipolar cycloaddition, the resulting products 14 will
contain a triazole ring system, a structural unit which is considered
to act as a peptide bond mimic (both the trans- and the cis-amide
bond conﬁgurations can be mimicked by the 1,4- and 1,5-triazoles,
respectively).14,29,36,37 Thus, such products can be considered to be
macrocyclic peptidomimetics, a sub-class of macrocycles which is
of considerable interest in drug discovery and which has attracted
signiﬁcant attention in recent years.14,38 Macrocyclisation by ring-
closing and ene-yne metathesis would furnish products contain-
ing synthetically versatile functional motifs (alkene and diene
units, respectively) that could potentially serve as synthetic handles
for further derivitisation around the macrocyclic cores. General
structural type 15 is non-peptidic, a sub-class of macrocyles which
is comparatively less-well explored in drug discovery.10
2.2. Proof of concept work
In order to establish the validity of the DOS strategy, the syn-
thesis of a representative member of each of the three different
general macrocyclic structural types 14e16 was targeted. We spe-
ciﬁcally chose compounds 19e21, which we envisaged could be
generated from building blocks 22e29 and 9 (Scheme 2).
In addition to demonstrating the feasibility of the DOS, these
speciﬁc compounds were selected as targets in order to probe both
the synthetic versatility of the DOS and also its’ capacity to furnish
macrocyles with certain interesting or desirable structural charac-
teristics. The target compounds covered a range of macrocyclic ring
sizes and included both cyclic and acyclic amine motifs, as well as
other functionalities and potential biomolecular interacting ele-
ments (e.g., hydrogen bond donors and acceptors). Each target
macrocycle also included a chiral centre, which we assumed could
be introduced through the use of chiral ‘carbonyl capping’ building
blocks (23, 26 and 28). If successful, this would demonstrate an-
other method to introduce stereochemical diversity into the mac-
rocycles through the building blocks (in addition to variation in the
scaffold-deﬁning elements), which should facilitate the probing of
three-dimensional chemical space around the ring architectures.
Target compounds 19 and 20 contained aryl halide motifs, which
could potentially be further functionalised via various metal-
catalysed cross-coupling processes. Successful synthesis of 19
would thus demonstrate that a functional group handle for deri-
vitisation around the macrocyclic core could be introduced into
compounds of the general form 14. In the case of the representativeexample of macrocyles of the general form 20, it was thought that it
would be interesting to examine whether an additional synthetic
handle for post-cyclisation structural elaboration could be installed
which was orthogonal to the alkene unit introduced during
macrocyclisation.
2.2.1. Building block synthesis. Building blocks 9, 22, 25, 27 and 29
could be obtained from commercial sources. Amino-alkyne build-
ing block 23 was readily accessed from commercially available
pyridine-acid 29 in three steps (Scheme 3). Amine protection
generated the N-Boc derivative 30. Propyl phosphonic acid anhy-
dride (T3P) mediated coupling with alkynyl amine 31 furnished
compound 32 and subsequent removal of the Boc group under
acidic conditions yielded the desired building block 23 (isolated as
the HCl-salt). Building block 28 could also be accessed (again as the
corresponding HCl-salt) from 30 by EDC-mediated coupling with
alkynyl alcohol 33 to form 34 followed by Boc deprotection. The
synthesis of acyclic amino-alkene 26was similarly straightforward.
EDC-mediated coupling of commercially available carboxylic acid
35 and alkenyl alcohol 36 proceeded smoothly to generate ester 37
and subsequent acid-mediated Boc group removal afforded the
target building block 26 (isolated as the HCl-salt). It was envisaged
that azido-bromo ‘hydroxyl capping’ building block 24 could be
generated in situ from the corresponding tosylate derivative 38
when required (see Section 2.2.2) which in turn was readily ob-
tained from alcohol 39.
2.2.2. Synthesis of target compound 19. The synthesis of compound
19 commenced with the esteriﬁcation of hydroxy benzoic acid
‘platform’ building block 22 to generate compound 40 (Scheme 4).
Coupling with ‘hydroxyl capping’ building block 24 (which was
formed in situ from 38), proceeded smoothly to afford compound
41. Subsequent saponiﬁcation of the ester moiety under basic
conditions provided derivative 42.39 Coupling with amine ‘carbonyl
capping’ building block 23 provided linear cyclization precursor 43
in a good yield. Pleasingly, 1,3-dipolar cycloaddition with copper
catalysis proceeded smoothly and with a high degree of regiose-
lectivity to furnish targetmacrocycle derivative 19 in a good yield.40
The cycloaddition of 43 under ruthenium catalysis was investigated
in an attempt to generate the regioisomeric macrocycle containing
the 1,5-disubstituted triazole ring system. Although there was ev-
idence for the formation of the desired product, it could not be
isolated. Attention then turned towards the use of the alternative
‘carbonyl capping’ building block 44 in the DOS of compounds of
the form 14. Compound 44 was readily prepared from L-proline by
an analogous route to the preparation of 23 (see Experimental
Section). Coupling of 42 with 44 afforded acyclic precursor 45 in
a high yield. Pleasingly, subsequent macrocyclisation under copper-
catalysis again proceeded smoothly to furnish compound 46, an-
other macrocycle of the general form 14.
2.2.3. Synthesis of target compounds 20 and 21 from salicylaldehyde
25. It was anticipated that target macrocyclic compounds 20 and
21 could both be accessed from salicylaldehyde 25 (Scheme 5).
Attachment of the appropriate ‘hydroxyl capping’ building
blocks 27 or 29 (couple stage) proceeded smoothly to furnish
compounds 47 and 48. Reductive amination of 47 with ‘carbonyl
capping’ building block 26 furnished cyclization precursor 49. In
the par stage of the synthesis, the ring-closing metathesis of 49
with Hoveyda-Grubbs second generation catalyst was attempted,
but no product formation was observed. It was thought that the
lack of reactivity might be the result of deactivation of the me-
tathesis catalyst via coordination to the free amine of substrate 49.
Thus, metathesis was attempted with the addition of one equiva-
lent of p-toluenesulfonic acid hydrate (PTSA$H2O) to the reaction
mixture in order to protonate the amine in situ. Pleasingly, this
Scheme 2. Proof-of-concept target macrocycles 19e21.
Scheme 3. Synthesis of building blocks.
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Scheme 4. Synthesis of macrocycles 19 and 46.
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was attributed to incomplete consumption of the starting material,
despite the prolonged reaction time). Knoevenagel condensation of
48with ‘spacer’ building block 9 (the second couple stage) affordedScheme 5. Synthesis of mcompound 50 and subsequent coupling with ‘carbonyl capping’
building block 28 (the third couple stage) led to the formation of
macrocyclisation precursor 51. In the pair stage of the synthesis,
intramolecular ene-yne metathesis successfully afforded targetacrocycles 20 and 21.
J.J. Ciardiello et al. / Tetrahedron 72 (2016) 3567e3578 3573compound 21. The isolated yield of 21 was relatively low, which
again could be attributed to incomplete consumption of starting
material.
3. Conclusions
Herein, we have described a new strategy for the expedient DOS
of novel and structurally diverse macrocyclic compounds which are
based around a variety of distinct molecular scaffolds. The synthetic
approach is based around the use of aromatic starting materials
that bear an electrophilic carbonyl group and a nucleophilic hy-
droxyl group. These are designed to serve as ‘platforms’ onto which
different building blocks can be attached to afford a range of dis-
tinct acyclic precursors. Subsequent intramolecular cyclisation re-
actions would then furnish different macrocyclic compounds. It
was anticipated that the new DOS strategy would allow access to
macrocyclic compounds of the general structural forms 14e16. In
a proof-of-concept study, the synthesis of four different novel
macrocyclic compounds 19e21 and 46, including representative
examples of each of the different macrocyclic structural forms, was
achieved. Each of these four previously unreported compoundswas
based around a distinct macrocyclic scaffold and contains func-
tional motifs that could potentially interact with biological targets.
These compounds are of signiﬁcant interest from both a biological
and synthetic perspective and their successful generation provides
a validation of our new DOS strategy for the synthesis of structur-
ally diverse macrocycles. We anticipate that this approach holds
signiﬁcant potential for library generation. It is step-efﬁcient, pro-
ceeds from readily available starting materials and is modular in
nature, which should allow for concise access to a diverse range of
molecular scaffolds through variation in the building blocks at-
tached to the core aromatic unit. The DOS strategy also features the
use of three different macrocyclisation techniques, which allows for
potential access to different structural motifs embedded within the
macrocyclic architectures. Thus, we believe that this new DOS
strategy represents a valuable contribution to the repertoire of
strategies available for the synthesis of the biologically interesting
macrocycle compound class. Larger library synthesis endeavours
using this DOS algorithm are on-going. These, and the results of
subsequent biological screening studies (which we hope will lead




All reagents and solvents were purchased from commercial
sources and used without further puriﬁcation unless otherwise
stated. All the experiments were carried out under a nitrogen at-
mosphere unless otherwise stated. Melting points were measured
using a B€uchi B545 melting point apparatus and are uncorrected.
Thin layer chromatography (TLC) was performed on precoated
Merck silica gel GF254 plates. IR spectra were recorded on a Per-
kineElmer Spectrum One (FT-IR) spectrophotometer. Flash column
chromatography was performed on silica gel (230e400 mesh). 1H
NMR and 13C NMR were recorded on a Bruker Avance 500 MHz
instrument in CDCl3, (CD3)2CO and DMSO-d6. HRMS was recorded
on a Micromass Q-TOF mass spectrometer or a Waters LCT Premier
Time of Flight mass spectrometer.
4.2. Experimental details and characterization data
4.2.1. Synthesis of (S)-1-Boc-piperidine-3-carboxylic acid (30). (S)-
Piperine-3-carboxylic acid (29) (4.00 g, 30.76 mmol) was dissolved
in THF (230 mL) and H2O (230 mL). Na2CO3 (12.0 g, 113 mmol) wasadded at rt and the solution cooled to 0 C. Boc-anhydride (7.38 g,
33.8 mmol) was added and the solution stirred at 0 C for 2 h and
then at rt for 12 h. The THF was removed under reduced pressure
and resulting aqueous solution acidiﬁed with 10% HCl to pH 4. The
aqueous layer was extracted with EtOAc (3100 mL). The organic
extracts were combined, washed with brine (80 mL) and dried
(Na2SO4). The solventwas removed under reduced pressure to yield
the title compound as a white solid (6.14 g, 87%). [a]D20 þ29.7 (c 1.0,
CHCl3). IR nmax (neat)/cm1: 3167 w br (OeH str), 1730 s (C]O str),
1653 s (C]O str). 1H NMR (500 MHz, DMSO-d6, 120 C): d 3.93 (1H,
dd, J 12.9, 4.4 Hz, eCH2e), 3.70 (1H, dt, J 12.9, 4.4 Hz, eCH2e), 3.02
(1H, dd, J 12.9, 9.6 Hz, eCH2), 2.94e2.87 (1H, m, eCH2e), 2.37e2.31
(1H, m, eCHe), 1.97e1.91 (1H, m, eCH2e), 1.70e1.55 (2H, m,
eCH2e), 1.46e1.35 (10H, m, eCH2e & CH3). 13C NMR (125 MHz,
DMSO-d6, 120 C): d 174.5, 154.5, 79.2, 45.7, 44.0, 41.2, 28.6, 27.1,
24.2. HRMS (ESIþ) m/z¼252.1212 [MþNa]þ found, C11H19O4Naþ
required 252.1206.
4.2.2. Synthesis of (S)-1-Boc-(prop-2-yn-1-yl)piperidine-3-
carboxamide (32). To a stirred solution of (S)-1-Boc-piperidine-3-
carboxylic acid (30) (1.00 g, 4.36 mmol) in EtOAc (35 mL), prop-
argylamine (31) (280 mL, 4.36 mmol) was added at rt and the re-
sultant solution cooled to 0 C. To this solution was added DIPEA
(1.5 mL, 8.80 mmol) and a solution of 50 wt. % T3P in EtOAc (3.4 mL,
5.72 mmol). The solutionwas stirred for 30min at 0 C before being
stirred at rt for 20 h. The reaction was quenched with H2O (5 mL)
and the aqueous layer extracted with EtOAc (25 mL). The organic
extracts were combined, dried (MgSO4) and the solvent removed
under reduced pressure to yield the title compound as awhite solid
(1.10 g, 95%). TLC Rf¼0.12 (PE 30-40/EtOAc 7:3). IR nmax (neat)/cm1:
3220 m (NeH str), 2967 m (CeH str), 2921 m (CeH str), 2860 m
(CeH str), 1684 s (C]O str), 1631 s (C]O str). 1H NMR (500 MHz,
CD3OD): d 4.07 (1H, br d, J 11.5 Hz, eCH2e), 3.96 (1H, d, J 16.5 Hz,
eCH2e), 3.92 (2H, d, J 2.5 Hz, eCH2e), 3.00e2.70 (2H, m, eCH2e),
2.56 (1H, t, J 2.5 Hz, eCH), 2.33e2.27 (1H, m,eCHe), 1.92e1.88 (1H,
m, eCH2e), 1.72e1.62 (3H, m, eCH2e), 1.44 (9H, s, eCH3). 13C NMR
(125 MHz, CD3OD): d 175.6, 156.4, 81.3, 80.6, 72.2, 45.7, 44.6, 44.1,
29.3, 28.9, 28.6, 25.5. HRMS (ESIþ) m/z¼289.1536 [MþNa]þ found,
C14H22O3N2Naþ required 289.1528.
4.2.3. Synthesis of (S)-N-(prop-2-yn-1-yl)piperidine-3-carboxamide
(23). (S)-1-Boc-(prop-2eyn-1-yl)piperidine-3-carboxamide (32)
(758 mg, 2.85 mmol) was dissolved in 4N HCl in 1,4-dioxane
(26 mL) and stirred at rt for 2 h after which the solvent was re-
moved under reduced pressure to yield the crude product as
a brown solid. The crude product with triturated with chloroform
to yield the title compound as a white salt (444 mg, 77%). IR nmax
(neat)/cm1: 3276 m (NeH str), 2931 w (CeH str), 1650 m (C]O
str). 1H NMR (500 MHz, CD3OD): d 3.96 (2H, d, J 2.5 Hz, eCH2e),
3.27e3.15 (3H, m, eCH2e), 3.11e3.06 (1H, m, eCH2e), 2.76e2.72
(1H, m, eCHe), 2.60 (1H, t, J 2.5 Hz, eCH), 2.02e1.89 (2H, m,
eCH2e), 1.82e1.73 (2H, m, eCH2e). 13C NMR (125 MHz, CD3OD):
d 174.2, 80.4, 72.3, 46.2, 45.1, 39.6, 29.4, 27.0, 21.2. HRMS (ESIþ) m/
z¼167.1180 [MþH]þ found, C9H15ON2þ required 167.1179.
4.2.4. Synthesis of 3-(but-3-yn-1-yl) (S)-1-Boc-piperidine-3-
carboxylate (34). To a stirred solution of 30 (3.00 g, 13.1 mmol) in
CH2Cl2 (30 mL), EDC (4.22 g, 22.0 mmol) was added at 0 C with
subsequent stirring for 40 min. To this solution was added DMAP
(348mg, 2.86mmol), DIPEA (9.12mL, 52.3 mmol) and 3-butyn-1-ol
(33) (1.98 mL, 26.2 mmol). The solution was warmed to rt and
stirred for 17 h. The solvent was removed under reduced pressure
after which EtOAc (50 mL) was added. The organic phase was
washed with 5% NaHCO3 (250 mL), 5% citric acid (50 mL), H2O
(30 mL) and then brine (30 mL). The organic extract was dried
(MgSO4) and the solvent removed under reduced pressure to yield
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TLC Rf¼0.37 (Hexane/EtOAc 4:1). Mp 72e74 C. [a]D20 þ28.1 (c¼1.0,
CHCl3). IR nmax (neat)/cm1: 3246 s (CeH str), 1726 s (C]O str),
1673 s (C]O str). 1H NMR (500 MHz, DMSO-d6, 120 C): d 4.15 (2H,
td, J 6.6, 1.6 Hz, eCH2e), 3.93 (1H, dd, J 13.2, 4.1 Hz, eCH2e), 3.68
(1H, dt, J 13.2, 4.1 Hz, eCH2e), 3.09 (1H, dd, J 13.2, 9.5 Hz, eCH2e),
2.98e2.92 (1H, m, eCH2e), 2.59e2.43 (4H, m, eCH2e, eCHe &
eCH), 1.99e1.91 (1H, m, eCH2e), 1.72e1.61 (2H, m, eCH2e),
1.47e1.37 (10H, m, eCH2e & eCH3). 13C NMR (125 MHz, DMSO-d6,
120 C): d 172.8, 154.5, 81.0, 79.2, 72.1, 62.4, 45.9, 44.0, 41.3, 28.6,
26.9, 24.1, 18.1. HRMS (ESIþ) m/z¼304.1510 [MþNa]þ found,
C15H23NO4Naþ required 304.1519.
4.2.5. Synthesis of but-3-yn-1-yl (S)-piperidine-3-carboxylate hy-
drochloride (28). 34 (140 mg, 498 mmol) was dissolved in 4N HCl in
dioxane (3 mL) and stirred for 3 h, after which the solvent was
removed under reduced pressure. To the residue was added H2O
(7 mL) and the solution freeze dried to yield the title compound as
a brown oil (100 mg, 92%). IR nmax (neat)/cm1: 3282 w (NeH str),
2944 m (CeH str), 1726 s (C]O str). 1H NMR (500 MHz, DMSO-d6,
120 C): d 9.53 (2H, br, -NH-), 4.22e4.15 (2H, m, eCH2e), 3.34 (1H,
dd, J 12.3, 3.4 Hz, eCH2e), 3.17 (1H, dt, J 12.6, 3.8 Hz, eCH2e),
2.97e2.92 (1H, m, eCH2e), 2.87e2.82 (1H, m, eCH2e), 2.67 (1H, t, J
2.8 Hz, eCH), 2.54 (2H, td, J 6.6, 2.8 Hz, eCH2e), 2.08e2.01 (1H, m,
eCH2e), 1.91e1.79 (2H, m, eCH2e), 1.69e1.60 (1H, m, eCH2e). 13C
NMR (125 MHz, DMSO-d6, 120 C): d¼171.6, 81.0, 72.4, 62.8, 44.3,
43.3, 38.4, 25.1, 21.2, 18.6. HRMS (ESIþ) m/z¼182.1183 [MþH]þ
found, C10H16NO2þ required 182.1181.
4.2.6. Synthesis of but-3-en-1-yl Boc-4-iodo-L-phenylalanine
(37). To a stirred solution of Boc-4-iodo-L-phenylalanine (2.00 g,
5.11 mmol) in CH2Cl2 (20 mL) was added EDC (2.34 g, 12.2 mmol),
DMAP (183 mg, 1.50 mmol) and 3-buten-1-ol (1.20 mL) at 0 C. The
solution was warmed to rt and stirred for 19 h. The solution was
diluted with CH2Cl2 (50 mL) and the organic phase washed with 5%
NaHCO3 (50 mL), H2O (30 mL) and then brine (30 mL). The organic
extract was dried (MgSO4) and the crude product puriﬁed by ﬂash
column chromatography eluting with 50% EtOAc in hexane to yield
the title compound as crystalline, yellow solid (1.70 g, 75%).
Mp¼75e77 C. TLC Rf¼0.70 (Hexane/EtOAc 1:1). [a]D20 þ26.1 (c 1.0,
CHCl3). IR nmax (neat)/cm1: 3373 m (NeH str), 2972 m (CeH str),
1726 s (C]O str), 1687 s (C]O str), 1514 s (C]C str), 1485 m (C]C
str),1443m (C]C str). 1H NMR (500MHz, DMSO-d6): d 7.62 (2H, d, J
8.2 Hz, ArH), 7.27 (1H, t, J 7.9 Hz, -NH-), 7.04 (2H, d, J 8.2 Hz, ArH),
5.71 (1H, ddq, J 17.4, 10.4, 6.7 Hz, eCHCH2), 5.07 (1H, d, J 17.1 Hz,
eCH2), 5.03 (1H, d, J 10.4 Hz, eCH2), 4.14e4.00 (3H, m, eCH2 &
eCH), 2.92 (1H, dd, J 13.7, 5.5 Hz, eCH2e), 2.79 (1H, dd, J 13.7,
9.8 Hz, eCH2e), 2.25 (2H, q, J 7.3 Hz, eCH2e), 1.31 (9H, s, eCH3). 13C
NMR (125 MHz, DMSO-d6): d¼172.4, 155.8, 137.8, 137.4, 134.7, 132.0,
117.7, 92.7, 78.9, 64.0, 55.5, 36.4, 32.9, 28.5. HRMS (ESIþ) m/
z¼468.0637 [MþNa]þ found, C18H24NO4127INaþ required 468.0642.
4.2.7. Synthesis of but-3-en-1-yl 4-iodo-L-phenylalanine hydrochlo-
ride (26). 37 (1.59 g, 3.57mmol) was dissolved in 4N HCl in dioxane
(24 mL) and stirred for 3 h, after which the solvent was removed
under reduced pressure. To the residuewas added H2O (25 mL) and
the solution freeze dried to yield the title compound as a crystalline
off-white solid (1.36 g, 100%). Mp 145e147 C. [a]D20 þ17.3 (c 1.0,
CHCl3). IR nmax (neat)/cm1: 3147 w (NeH str), 2845 m (CeH str),
1738 s (C]O str), 1641 w (C]C str), 1606 w (C]C str). 1H NMR
(500 MHz, DMSO-d6): d 7.69 (2H, d, J 8.2 Hz, ArH), 7.05 (2H, d, J
8.5 Hz, ArH), 5.64 (1H, ddq, J 17.0, 10.2, 6.5 Hz, eCHCH2), 5.08e5.01
(2H, m,eCH2), 4.23 (1H, dd, J 7.5, 6.1 Hz,eCHe), 4.10 (2H, t, J 6.1 Hz,
eCH2e), 3.10 (1H, dd, J 14.0, 6.1 Hz, eCH2e), 3.00 (1H, dd, J 14.0,
7.5 Hz, eCH2e), 2.24 (2H, q, J 6.8 Hz, eCH2e).13C NMR (125 MHz,
DMSO-d6: d 169.1, 137.7, 134.6, 134.3, 132.1, 117.8, 93.8, 65.1, 53.2,35.7, 32.4). HRMS (ESIþ) m/z¼346.0317 [MþH]þ found,
C13H17NO2127Iþ required 346.0304.
4.2.8. Synthesis of 5-azidopentyl tosylate (38). To a stirred solution
of 5-azidopentyl alcohol (39) (4.44 g, 34.3 mmol) in CH2Cl2
(213 mL) was added TEA (4.78 mL) and TsCl (9.82 g, 51.5 mmol) at
0 C. The solution was allowed to warm to rt and stirred for 19 h.
CH2Cl2 (100 mL) was added and the organic layer washed with H2O
(2100 mL) and brine (50 mL). The organic extract was dried
(MgSO4) and the solvent removed under reduced pressure. The
crude product puriﬁed by ﬂash column chromatography, eluting
with a gradient from 5% to 20% EtOAc in hexane to yield the title
compound as a colourless oil (6.59 g, 68%). TLC Rf¼0.19 (Hexane/
EtOAc 9:1). IR nmax (neat)/cm1: 2937 m (CeH str), 2871 m (CeH
str), 2091 s (N3 str), 1596m (C]C str), 1451m (C]C str), 1350 s (S]
O str), 1176 s (S]O str). 1H NMR (400 MHz, CDCl3): d 7.77 (2H, d, J
6.4 Hz, ArH), 7.33 (2H, d, J 6.4 Hz, ArH), 4.01 (2H, t, J 6.4 Hz, eCH2e),
3.21 (2H, t, J¼6.8 Hz, eCH2e), 2.42 (3H, s, eCH3), 1.69e1.62 (2H, m,
eCH2e), 1.56e1.48 (2H, m, eCH2e), 1.41e1.34 (2H, m, eCH2e). 13C
NMR (100 MHz, CDCl3): d 144.8, 132.9, 129.8, 127.8, 70.1, 51.0, 28.3,
28.1, 22.6, 21.6. HRMS (ESIþ) m/z¼306.0895 [MþNa]þ found,
C12H17O3N3SNaþ required 306.0883.
4.2.9. Synthesis of ethyl 3-bromo-5-hydroxybenzoate (40). To a stir-
red solution of 3-bromo-5-hydroxy benzoic acid (22) (5.19 g,
23.9 mmol) in EtOH (50 mL), H2SO4 (1 mL) was added at rt and the
solution reﬂuxed at 70 C for 72 h. The solvent was removed under
reduced pressure and to it added EtOAc (100 mL). The organic
phase was washed with satd NaHCO3 (250 mL) and brine (50 mL).
The organic extract was dried (MgSO4) and the solvent removed
under reduced pressure to yield the title compound as an orange
solid (5.48 g, 94%). Mp 99e101 C (lit. value 96 C). TLC Rf¼0.25 (PE
30-40/EtOAc 9:1). IR nmax (neat)/cm1: 3392 m br (OeH str), 3094
w (CeH str), 2972 w (CeH str), 2926 w (CeH str), 1691 s (C]O str),
1603m (C]C str), 1588m (C]C str), 1480m (C]C str), 1461m (C]
C str), 1439 m (C]C str). 1H NMR (400 MHz, CDCl3): d 7.72 (1H, d, J
1.2 Hz, ArH), 7.53 (1H, dd, J 2.4, 1.2 Hz, ArH), 7.22 (1H, dd, J 2.4,
2.0 Hz, ArH), 4.37 (2H, q, J 7.2 Hz, eCH2e), 1.38 (3H, t, J 7.2 Hz,
eCH3). 13C NMR (100MHz, CDCl3): d 165.7,156.6,132.9,124.8, 123.3,
122.8, 115.5, 61.8, 14.2. HRMS (ESIþ)m/z¼266.9634 [MþNa]þ found,
C9H9O3BrNaþ required 266.9627.
These data are consistent with those previously reported.41
4.2.10. Synthesis of ethyl 3-((5-azidopentyl)oxy)-5-bromobenzoate
(41). A solution of 38 (4.65 g, 16.4 mmol) and LiBr (4.27 g,
49.2 mmol) in acetone (53 mL) was reﬂuxed at 70 C for 18 h. The
solutionwas ﬁltered to remove the precipitate yielding a solution of
the corresponding bromide 24 in acetone (53 mL). Ethyl 3-bromo-
5-hydroxybenzoate (40) (1.34 g, 5.47 mmol), KI (83 mg, 500 mmol),
18-crown-6 (66 mg, 250 mmol) and K2CO3 (2.27 g, 16.4 mmol) were
added to the solution of 24 at rt. The mixture was reﬂuxed at 70 C
for 42 h. The solvent was then removed under reduced pressure,
EtOAc (60 mL) added and the organic layer washed with H2O
(60mL). The aqueous layer was separated and extractedwith EtOAc
(60 mL). The organic extracts were combined, washed with H2O
(60 mL) and brine (30 mL), dried (MgSO4) and the solvent removed
under reduced pressure. The crude product was puriﬁed by ﬂash
column chromatography, eluting with a gradient from 2% to 4%
EtOAc in petroleum ether 30e40 to yield the title compound as an
orange oil (1.94 g, 98%). TLC Rf¼0.29 (Hexane/EtOAc 19:1). IR nmax
(neat)/cm1: 2932 m (CeH str), 2086 s (N3 str), 1719 s (C]O str),
1593m (C]C str), 1570m (C]C str), 1439m (C]C str), 1391 w (C]
C str), 1360 w (C]C str). 1H NMR (500 MHz, CDCl3): d 7.74 (1H, t, J
1.5 Hz, ArH), 7.47 (1H, dd, J 2.5, 1.5 Hz, ArH), 7.21 (1H, s, ArH), 4.35
(2H, q, J 7.0 Hz, eCH2e), 3.99 (2H, t, J 6.0 Hz, eCH2e), 3.31 (2H, t, J
7.0 Hz, eCH2e), 1.84e1.79 (2H, m, eCH2e), 1.70e1.64 (2H, m,
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NMR (125 MHz, CDCl3): d 165.6, 160.0, 133.5, 125.2, 123.0, 122.8,
114.4, 68.6, 61.9, 51.7, 29.0, 23.7, 14.7. HRMS (ESIþ) m/z¼378.0430
[MþNa]þ found, C14H18O3N3BrNaþ required 378.0424.
4.2.11. Synthesis of 3-((5-azidopentyl)oxy)-5-bromobenzoic acid
(42). To a stirred solution of ethyl 3-((5-azidopentyl)oxy)-5-
bromobenzoate (41) (1.57 g, 4.41 mmol) in EtOH (13.2 mL) and
THF (4.4 mL) was added a solution of LiOH (231 mg, 5.50 mmol) in
H2O (4.4 mL) at rt. The solution was stirred for 16 h and then
acidiﬁed with 10% HCl to pH 3. The aqueous layer was extracted
with EtOAc (280 mL) and the organic extracts were combined,
washed with H2O (50 mL), brine (50 mL) and dried (MgSO4). The
solvent was removed under reduced pressure to yield the title
compound as an orange solid (1.30 g, 90%). Mp 102e104 C. IR nmax
(neat)/cm1: 2942 w br (OeH str), 2081 s (N3 str), 1686 s (C]O str),
1590m (C]C str), 1573m (C]C str), 1461m (C]C str), 1432m (C]
C str), 1418 m (C]C str), 1398 m (C]C str). 1H NMR (400 MHz,
CDCl3): d 7.81 (1H, t, J 1.6 Hz, ArH), 7.53e7.51 (1H, m, ArH), 7.27 (1H,
dd, J 1.8, 1.6 Hz, ArH), 4.00 (2H, t, J 6.2 Hz, eCH2e), 3.30 (2H, t, J
6.4 Hz, eCH2e), 1.87e1.80 (2H, m, eCH2e), 1.71e1.63 (2H, m,
eCH2e), 1.61e1.57 (2H, m, eCH2e). 13C NMR (100 MHz, CDCl3):
d 169.3, 159.7, 131.5, 125.4, 123.4, 122.8, 114.5, 68.2, 51.3, 28.6, 23.3.
HRMS (ESIþ) m/z¼350.0112 [MþNa]þ found, C12H14O3N3BrNaþ re-
quired 350.0111.
4.2.12. Synthesis of azido-alkyne (43). (S)-N-(prop-2-yn-1-yl)pi-
peridine-3-carboxamide (23) (31 mg, 150 mmol) and 3-((5-
azidopentyl)oxy)-5-bromobenzoic acid (42) (50 mg, 150 mmol)
were dissolved in EtOAc (1.2 mL) at rt and then cooled to 0 C. To
this solution was added DIPEA (100 mL, 600 mmol) and a solution of
50 wt. % T3P in EtOAc (120 mL, 195 mmol). The solutionwas stirred at
0 C for 30 min before being stirred at rt for 20 h. The reaction was
quenched with H2O (20 mL) and EtOAc (20 mL) was added. The
organic layer was separated and washed with 5% citric acid
(220mL), 5% NaHCO3 (20mL) and then brine (20mL). The organic
extract was dried (MgSO4) and the solvent removed under reduced
pressure. The crude product was puriﬁed with ﬂash column chro-
matography, eluting with 60% EtOAc in petroleum ether 30e40 to
yield the title compound as a colourless oil (49 mg, 69%). TLC
Rf¼0.25 (PE 30-40/EtOAc 4:6). IR nmax (neat)/cm1: 2937 w (CeH
str), 2865 w (CeH str), 2096 s (N3 str), 1623 m (C]O str), 1563 m
(C]C str), 1464 m (C]C str), 1434 m (C]C str). 1H NMR (500 MHz,
DMSO-d6): d 7.26 (1H, s, ArH), 7.02 (1H, s, ArH), 6.73 (1H, s, ArH),
4.57e4.14 (1H, m, eCH2e), 4.06 (2H, t, J 7.0 Hz, eCH2e), 3.93 (2H, s,
eCH2e), 3.64e3.57 (1H, m, eCH2e), 3.34 (2H, t, J 7.0 Hz, eCH2e),
3.18e3.03 (2H, m, eCH2e), 2.55e2.36 (2H, m, eCHe & eCH),
2.00e1.72 (4H, m, eCH2e), 1.61e1.21 (6H, m, eCH2e). 13C NMR
(125 MHz, DMSO-d6)eExists as a mixture of rotamers: d 174.1,
170.6, 161.5, 139.8, 124.0, 122.6, 120.1, 113.0, 80.5, 72.2, 69.5, 52.4,
50.8, 45.6, 44.1, 43.6, 29.7, 29.4, 28.7, 26.1, 25.0. HRMS (ESIþ) m/
z¼476.1313 [MþH]þ found, C21H27O3N5Brþ required 476.1297.
4.2.13. Synthesis of macrocycle (19). To a solution of 43 (17 mg,
36.0 mmol) in THF (20 mL) was added CuI (13.6 mg, 71.0 mmol) and
DIPEA (18 mL, 107 mmol) at rt. The solution was reﬂuxed at 70 C for
44 h. The solvent was removed under reduced pressure and the
crude product puriﬁed by ﬂash column chromatography, eluting
with 5% MeOH in EtOAc to yield the title compound as a colourless
oil (14.3 mg, 30.0 mmol, 83%). TLC Rf¼0.15 (EtOAc/MeOH 19:1). IR
nmax (neat)/cm1: 2942 w (CeH str), 2865 w (CeH str), 1661 m (C]
O str), 1630 m (C]O str), 1603 m (C]C str), 1560 m (C]C str), 1467
m (C]C str), 1449 m (C]C str), 1436 m (C]C str). 1H NMR
(400 MHz, CD3OD): d 7.80 (1H, s, eCHe), 7.15 (1H, t, J 2.0 Hz, ArH),7.09 (1H, s, ArH), 6.78 (1H, s, ArH), 4.78 (1H, d, J 14.8 Hz, eCH2e),
4.57e4.32 (3H, m,eCH2e), 4.04e3.92 (3H, m,eCH2e), 3.72 (1H, d, J
13.6 Hz, eCH2e), 3.13 (1H, dd, J 13.6, 10.0 Hz, eCH2e), 2.88e2.81
(1H, m, eCH2e), 2.47e2.42 (1H, m, eCHe), 2.13e1.53 (6H, m,
eCH2e), 1.52e1.47 (2H, m, eCH2e), 1.38e1.12 (2H, m, eCH2-). 13C
NMR (100 MHz, CD3OD): d 173.4, 168.4, 159.1, 137.8, 123.3, 122.3,
116.2, 112.8, 67.3, 50.1, 49.5, 43.5, 42.2, 33.5, 29.1, 28.2, 27.9, 24.0,
23.1. HRMS (ESIþ) m/z¼476.1306 [MþH]þ found, C21H27O3N5Brþ
required 476.1292.
4.2.14. Synthesis of (S)-N-(prop-2-yn-1-yl)proline carboxamide hy-
drochloride (44). To a stirred solution of L-proline (5.00 g,
43.4 mmol) in THF (325 mL) and H2O (325 mL), Na2CO3 (17.3 g,
162mmol) was added at rt and the resultant solution cooled to 0 C.
Following the addition of Boc-anhydride (10.4 g, 47.8 mmol), the
solution was stirred at 0 C for 2 h and then at rt for 18 h. The THF
was removed under reduced pressure and the resulting aqueous
solution acidiﬁed with 1M HCl to pH 4. The aqueous layer was
extracted with EtOAc (350 mL) and the organic extracts were
combined and dried (Na2SO4). The solvent was removed under
reduced pressure to yield N-Boc-L-proline. To a stirred solution of
N-Boc-L-proline (2.00 g, 9.29 mmol) in EtOAc (70 mL), propargyl-
amine (31) (600 mL, 9.34 mmol) was added at rt and then cooled to
0 C. To this solution was added DIPEA (3.2 mL, 18.8 mmol) and
a solution of 50 wt. % T3P in EtOAc (7.25 mL, 12.2 mmol). The so-
lution was stirred at 0 C for 30 min before being stirred at rt for
20 h. The reaction was quenched with H2O (50 mL), EtOAc (50 mL)
was added and the organic layer separated and washed with 5%
NaHCO3 (50 mL), 5% citric acid (50 mL) and brine (50 mL). The
organic extract was dried (MgSO4) and the solvent removed under
reduced pressure to yield (S)-1-Boc-(prop-2-yn-1-yl)proline car-
boxamide. (S)-1-Boc-(prop-2-yn-1-yl)proline carboxamide
(734 mg, 2.80 mmol) was dissolved in 4N HCl in 1,4-dioxane
(26 mL) and stirred at rt for 2 h after which the solvent was re-
moved under reduced pressure to yield the crude product as
a brown solid. The crude product with triturated with chloroform
to yield the title compound as a white salt (470 mg, 47% over three
steps). IR nmax (neat)/cm1: 3235 m (NeH str), 2911 m (CeH str),
1687m (C]O str). 1H NMR (400MHz, CD3OD): d 4.14 (1H, t, J 7.6 Hz,
eCHe), 3.93 (2H, d, J 2.4 Hz, eCH2e), 3.31e3.22 (2H, m, eCH2e),
2.56 (1H, t, J 2.4 Hz, eCH), 2.35e2.30 (1H, m, eCH2e), 1.97e1.87
(3H, m, eCH2e). 13C NMR (100 MHz, CD3OD): d 169.2, 79.9, 72.8,
61.1, 47.3, 30.8, 29.8, 25.0. HRMS (ESIþ) m/z¼153.1021 [MþH]þ
found, C8H13ON2þ required 153.1022.
4.2.15. Synthesis of azido-alkyne (45). (S)-N-(prop-2-yn-1-yl)pro-
line carboxamide hydrochloride (44) (28 mg, 150 mmol) and 3-((5-
azidopentyl)oxy)-5-bromobenzoic acid (42) (50 mg, 150 mmol)
were dissolved in EtOAc (1.2 mL) at rt and then cooled to 0 C. To
this solution was added DIPEA (100 mL, 600 mmol) and a solution of
50 wt. % T3P in EtOAc (120 mL,195 mmol). The solutionwas stirred at
0 C for 30 min before being stirred at rt for 20 h. The reaction was
quenched with H2O (20 mL) and EtOAc (20 mL) was added. The
organic layer was separated and washed with 5% citric acid
(220mL), 5% NaHCO3 (20mL) and then brine (20mL). The organic
extract was dried (MgSO4) and the solvent removed under reduced
pressure. The crude product was puriﬁed with ﬂash column chro-
matography, eluting with 60% EtOAc in petroleum ether 30e40 to
yield the title compound as a colourless oil (65 mg, 93%). TLC
Rf¼0.25 (PE 30-40/EtOAc 4:6). IR nmax (neat)/cm1: 3291 m (NeH
str), 2937 w (CeH str), 2876 w (CeH str), 2096 s (N3 str), 1661 m
(C]O str), 1621 m (C]O str), 1568 m (C]C str), 1454 m (C]C str),
1431 m (C]C str), 1413 m (C]C str). 1H NMR (500 MHz, DMSO-d6,
120 C): d 7.20 (1H, s, ArH), 7.10 (1H, s, ArH), 6.68 (1H, s, ArH), 4.41
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3.58e3.46 (2H, m,eCH2e), 3.34 (2H, t, J 6.8 Hz,eCH2e), 2.79 (1H, t,
J 2.5 Hz, eCH), 2.20e2.16 (1H, m, eCH2e), 1.94e1.83 (3H, m,
eCH2e), 1.81e1.75 (2H, m, eCH2e), 1.69e1.62 (2H, m, eCH2e),
1.57e1.52 (2H, m, eCH2e). 13C NMR (125 MHz, DMSO-d6, 120 C):
d 171.8, 167.6, 159.7, 140.3, 122.4, 122.3, 118.9, 113.1, 81.4, 73.5, 68.4,
61.2, 51.0, 47.2, 30.1, 28.5, 25.4, 23.2. HRMS (ESIþ) m/z¼462.1137
[MþH]þ found, C20H25O3N5Brþ required 462.1135.
4.2.16. Synthesis of macrocycle (46). To a solution of 45 (40.0 mg,
87.0 mmol) in THF (40 mL) was added CuI (28.4 mg, 150 mmol) and
DIPEA (42.0 mL, 240 mmol) at rt. The solution was reﬂuxed at 70 C
for 20 h. The solvent was removed under reduced pressure and the
crude product puriﬁed by ﬂash column chromatography, eluting
with 5% MeOH in EtOAc to yield the title compound as a colourless
oil (34.7 mg, 87%). TLC Rf¼0.15 (EtOAc/MeOH 19:1). IR nmax (neat)/
cm1: 2932 w (CeH str), 2876 w (CeH str), 1618 m (C]O str), 1601
m (C]C str),1560m (C]C str), 1451m (C]C str),1436m (C]C str),
1413 m (C]C str). 1H NMR (400MHz, CD3OD): d 7.76 (1H, s,eCHe),
7.16 (1H, s, ArH), 7.13 (1H, s, ArH), 6.67 (1H, s, ArH), 4.57 (1H, d, J
15.2 Hz, eCH2e), 4.44e4.50 (2H, m, eCH2e), 4.29e4.23 (2H, m,
eCH2e & eCHe), 3.90e3.88 (2H, m, eCH2e), 3.78e3.67 (2H, m,
eCH2e), 2.22e1.94 (6H, m, eCH2e), 1.81e1.75 (2H, m, eCH2e),
1.42e1.25 (2H, m, eCH2e). 13C NMR (100 MHz, CD3OD): d 174.3,
170.1, 160.8, 146.2, 140.4, 124.6, 124.4, 123.0, 117.7, 114.5, 68.3, 64.4,
50.4, 47.9, 35.8, 33.1, 29.1, 27.8, 23.2, 22.4. HRMS (ESIþ) m/
z¼462.1145 [MþH]þ found, C20H25O3N5Brþ required 462.1135.
4.2.17. Synthesis of 2-(allyloxy)benzaldehyde (47). To a stirred so-
lution of salicylaldehyde (20.0 g,164mmol) in acetonitrile (200mL)
was added allylbromide (27) (29.0 mL, 333 mmol), KI (544 mg,
3.28 mmol), 18-crown-6 (432 mg, 1.64 mmol) and K2CO3 (66.0 g,
478 mmol) at rt after which the solution was reﬂuxed at 75 C for
18 h. The K2CO3 was ﬁltered off and the solvent removed under
reduced pressure. H2O (100 mL) was added and the aqueous layer
extracted with EtOAc (2100 mL). The organic layers were com-
bined, washed with brine (50 mL), dried (Na2SO4) and the solvent
removed under reduced pressure to yield the title compound as an
orange oil (24.2 g, 84%). TLC Rf¼0.28 (Hexane/EtOAc 19:1). IR nmax
(neat)/cm1: 2861 w (CeH str), 1681 s (C]O str), 1598 s (C]C str),
1483 m (C]C str), 1457 m (C]C str). 1H NMR (400 MHz, CDCl3):
d 10.51 (1H, s,eCHO), 7.80 (2H, dd, J 7.5,1.7 Hz, ArH), 7.50 (1H, ddd, J
8.5, 7.5, 2.0 Hz, ArH), 6.99 (1H, t, J 7.5 Hz, ArH), 6.95 (1H, d, J 8.5 Hz,
ArH), 6.10e6.00 (1H, m,eCHCH2), 5.43 (1H, dq, J 17.4, 1.7 Hz,eCH2),
5.31 (1H, dq, J 10.6,1.4 Hz,eCH2), 4.63 (1H, dt, J¼5.1,1.4 Hz,eCH2e).
13C NMR (125 MHz, CDCl3): d 189.7, 160.9, 135.9, 132.4, 128.4, 125.1,
120.9, 118.1, 112.9, 69.2. HRMS (ESIþ)m/z¼163.0751 [MþH]þ found,
C10H11O2þ required 163.0754.
4.2.18. Synthesis of 2-(but-3-en-1-yloxy)benzaldehyde (48). To
a stirred solution of salicylaldehyde (1.00 g, 8.19 mmol) in aceto-
nitrile (10 mL) was added 4-bromobut-1-ene (29) (2.90 mL,
16.2 mmol), KI (136 mg, 819 mmol), 18-crown-6 (108 mg, 409 mmol)
and K2CO3 (3.30 g, 23.9 mmol) at rt after which the solution was
reﬂuxed at 75 C for 18 h. The solvent was removed under reduced
pressure, H2O (50 mL) was added and the aqueous layer extracted
with EtOAc (250 mL). The organic layers were combined, washed
with brine (50 mL), dried (Na2SO4) and the solvent removed under
reduced pressure to yield the title compound as a yellow oil (1.40 g,
97%). TLC Rf¼0.25 (Hexane/EtOAc; 19:1). IR nmax (neat)/cm1: 2936
w (CeH str), 1685 s (C]O str), 1600 s (C]C str), 1485 s (C]C str),
1459 s (C]C str).1H NMR (400 MHz, CDCl3): d 10.49 (1H, s, eCHO),
7.82 (1H, dd, J 7.7, 1.8 Hz, ArH), 7.52 (1H, dt, J 7.2, 1.8 Hz, ArH), 7.01
(1H, t, J 7.8 Hz, ArH), 6.96 (1H, d, J 8.4 Hz, ArH), 5.89 (1H, ddt, J 17.1,
10.3, 6.8 Hz,eCHCH2), 5.18 (1H, dq, J 17.1, 1.6 Hz,eCHCH2), 5.12 (1H,
dq, J 10.2,1.7 Hz,eCHCH2), 4.13 (2H, t, J 6.5 Hz,eCH2e), 2.60 (2H, tq,J 6.6, 1.4 Hz, eCH2e). 13C NMR (100 MHz, CDCl3): d 189.9, 161.3,
135.9, 134.0, 128.2, 125.0, 120.7, 117.6, 112.5, 67.7, 33.5. HRMS (ESIþ):
m/z¼199.0723 [MþNa]þ found, C11H12O2Naþ required 199.0730.
4.2.19. Synthesis of but-3-en-1-yl (S)-2-((2-(allyloxy)benzyl)amino)-
3-(4-iodophenyl)propanoate (49). To a stirred solution of 47 (50 mg,
308 mmol) and 26 (130 mg, 341 mmol) in THF (3 mL) was added
NaBH(OAc)3 (290 mg, 1.37 mmol) at rt, after which the solutionwas
stirred for 18 h. The reaction was quenched with 1M NaOH (10 mL)
and extracted with EtOAc (320 mL). The organic layers were
combined and washed with brine (20 mL). The organic extract was
dried (MgSO4) and the crude product puriﬁed by ﬂash column
chromatography, eluting with a gradient from 10% to 15% EtOAc in
petroleum ether 30e40 to yield the title compound as a pale yellow
oil (73.5 mg, 49%). TLC Rf¼0.47 (PE 30-40/EtOAc 7:3). [a]D20 þ6.6 (c
1.0, CHCl3). IR nmax (neat)/cm1: 2960 w (CeH str), 2861 w (CeH
str), 1728 s (C]O str), 1643 w (C]C str), 1602 w (C]C str), 1588 w
(C]C str). 1H NMR (500 MHz, CDCl3): d 7.55 (2H, d, J 8.5 Hz, ArH),
7.19 (1H, td, J 7.6, 1.8 Hz, ArH), 7.13 (1H, dd, J 7.3, 1.8 Hz, ArH),
6.89e6.86 (3H, m, ArH), 6.77 (1H, d, J 7.6 Hz, ArH), 5.95 (1H, ddt, J
17.4, 10.4, 4.9 Hz, eCHCH2), 5.68 (1H, ddt, J 17.1, 10.4, 6.7 Hz,
eCHCH2), 5.35 (1H, dq, J 17.1, 1.5 Hz, eCH2), 5.24 (1H, dq, J 10.7,
1.5 Hz,eCH2), 5.09e5.04 (2H, m,eCH2), 4.48e4.38 (2H, m,eCH2e),
4.06 (2H, t, J 6.7 Hz, eCH2e), 3.85 (1H, d, J 13.4 Hz, eCH2e), 3.65
(1H, d, J 13.4 Hz,eCH2e), 3.47 (1H, dd, J 7.6, 6.1 Hz,eCHe), 2.90 (1H,
dd, J 13.7, 6.1 Hz, eCH2e), 2.83 (1H, dd, J 13.7, 7.6 Hz, eCH2e), 2.30
(2H, qdd, J 6.7, 1.5, 1.2 Hz, eCH2e). 13C NMR (125 MHz, CDCl3):
d 174.1, 156.6, 137.4, 137.1, 133.8, 133.2, 131.2, 129.9, 128.3, 127.7,
120.5, 117.3, 117.0, 111.4, 91.9, 68.5, 63.7, 61.7, 47.6, 39.0, 33.0. HRMS
(ESIþ) m/z¼492.1024 [MþH]þ found, C23H27NO3127INaþ required
492.1030.
4.2.20. Synthesis of macrocycle (20). To a degassed solution of 49
(34.3 mg, 73.9 mmol) in CH2Cl2 (125 mL) was added PTSA.H2O
(15.2 mg, 79.9 mmol) under an argon atmosphere. The reaction was
subsequently reﬂuxed at 55 C for 1 h after which was added
HoveydaeGrubbs second generation catalyst (4.5 mg, 7.21 mmol)
followed by stirring for 72 h. The solution was degassed a second
time and to the solution was added HoveydaeGrubbs second
generation catalyst (6.3mg, 7.39 mmol) under an argon atmosphere.
The reaction was subsequently reluxed at 55 C for 16 h. The re-
action was quenched with NaHCO3 (30 mL) and the solvent re-
moved under reduced pressure. The aqueous layer was extracted
with CH2Cl2, after which the organic phases were combined,
washed with brine (30 mL) and dried (MgSO4). The crude product
was puriﬁed by ﬂash column chromatography, eluting with 30%
EtOAc in petroleum ether 30e40 to yield the title compound as
a colourless oil (9.0 mg, 26%). TLC Rf¼0.25 (PE 30-40/EtOAc 7:3).
[a]D20 þ37.1 (c 1.0, CHCl3). IR nmax (neat)/cm1: 2921 w (CeH str),
1728 s (C]O str), 1600 w (C]C str), 1586 w (C]C str). 1H NMR
(500 MHz, CDCl3): d 7.56 (2H, d, J 8.2 Hz, ArH), 7.23 (1H, td, J 7.9,
1.5 Hz, ArH), 7.11 (1H, dd, J 7.3, 1.8 Hz, ArH), 6.93e6.89 (2H, m, ArH),
6.87 (2H, d, J 8.2 Hz, ArH), 5.98e5.91 (1H, m, eCHCHe), 5.79e5.73
(1H, m,eCHCHe), 4.50 (1H, dd, J 10.4, 6.7 Hz,eCH2e), 4.40 (1H, dd,
J 10.7, 7.9 Hz, eCH2e), 4.22e4.13 (2H, m, eCH2e), 3.82 (1H, d, J
12.5 Hz,eCH2e), 3.62 (1H, d, J 12.5 Hz, eCH2e), 3.35 (1H, t, J 6.7 Hz,
eCHe), 2.90 (1H, dd, J 13.7, 6.4 Hz, eCH2e), 2.83 (1H, dd, J 13.7,
7.0 Hz, eCH2e), 2.56e2.40 (2H, m, eCH2e). 13C NMR (125 MHz,
CDCl3): d 173.2, 157.3, 137.4, 127.7, 137.3, 133.9, 131.3, 130.9, 128.7,
126.2, 121.2, 112.4, 91.8, 62.6, 62.3, 60.9, 47.6, 38.6, 27.9. HRMS
(ESIþ) m/z¼464.0740 [MþH]þ found, C21H23NO3127Iþ required
464.0723.
4.2.21. Synthesis of 2-(but-3-en-1-yloxy)trans-cinnamic acid
(50). To a stirred solution of 48 (1.18 g, 6.76 mmol) in toluene
(120mL) was addedmalonic acid (9) (780mg, 7.45mmol), pyridine
J.J. Ciardiello et al. / Tetrahedron 72 (2016) 3567e3578 3577(610 mL, 7.57 mmol) and piperidine (160 mL, 1.62 mmol). The solu-
tion was reﬂuxed at 120 C with a DeaneStark apparatus for 20 h.
The reaction was quenched with 3M HCl and the solvent removed
under reduced pressure. H2O (50 mL) was added and the aqueous
layer extracted with EtOAc (250 mL). The organic layers were
combined, washed with brine (50 mL), dried (Na2SO4) and the
solvent removed under reduced pressure. The crude product was
puriﬁedwith ﬂash column chromatography, elutingwith a gradient
from 20% to 30% EtOAc in hexane and thenwith 10%MeOH in EtOAc
to yield the title compound as an amorphous orange solid (943 mg,
64%). Mp 78e80 C. TLC Rf¼0.25 (Hexane/EtOAc 7:3). IR nmax (neat)/
cm1: 2917 w br (OeH str), 1677 s (C]O str), 1619 s (C]C str), 1596
s (C]C str), 1491m (C]C str), 1475m (C]C str) 1H NMR (500MHz,
CDCl3): d 8.08 (1H, d, J 16.2 Hz, eCHCHe), 7.52 (1H, dd, J 7.6, 1.5 Hz,
ArH), 7.35 (1H, ddd, J 8.2, 7.6, 1.8 Hz, ArH), 6.97 (1H, t, J 7.6 Hz, ArH),
6.92 (1H, d, J 8.2 Hz, ArH), 6.60 (1H, d, J 16.2 Hz,eCHCHe), 5.93 (1H,
ddt, J 17.1, 10.0, 6.7 Hz, eCHCH2e), 5.23 (1H, dq, J 17.4, 1.8 Hz,
eCHCH2e), 5.16 (1H, dq, J 10.4, 1.8 Hz, eCHCH2e), 4.11 (2H, t, J
6.4 Hz, eCH2e), 2.63 (2H, tq, J 6.7, 1.5 Hz, eCH2e). 13C NMR
(125 MHz, CDCl3): d 172.2, 157.9, 142.5, 134.1, 131.8, 129.6, 123.2,
120.8, 117.8, 117.6, 112.1, 67.7, 33.7. HRMS (ESIþ) m/z¼219.1009
[MþH]þ found, C13H15O3þ required 219.1016.
4.2.22. Synthesis of amide (51). 28 (222 mg, 1.02 mmol) and 50
(267mg, 1.22 mmol) were dissolved in EtOAc (10 mL) at rt and then
cooled to 0 C. To this solution was added DIPEA (838 mL,
4.81 mmol) and a solution of 50% T3P in EtOAc (970 mL, 1.63 mmol).
The solution was stirred at 0 C for 30 min and rt for 18 h. The
reactionwas quenched with H2O (100 mL) and EtOAc (100 mL) was
added. The organic layer was separated and washed with 5%
NaHCO3 (2100mL), 5% citric acid (100mL) and then brine (70mL).
The organic extract was dried (MgSO4) and the solvent removed
under reduced pressure to yield the title compound as a colourless
oil (280 mg, 72%). TLC Rf¼0.72 (PE 30-40/EtOAc 4:6). 1H NMR
(500MHz, DMSO-d6, 120 C): d 7.68 (1H, d, J 15.5 Hz,eCHCHe), 7.61
(1H, d, J 7.9 Hz, ArH), 7.33 (1H, t, J 8.2 Hz, ArH), 7.12 (1H, d, J 15.8 Hz,
eCHCHe), 7.07 (1H, d, J 8.2 Hz, ArH), 6.99 (1H, t, J 7.8 Hz, ArH),
6.00e5.89 (1H, m,eCHCH2), 5.20 (1H, d, J 17.3 Hz,eCH2e), 5.11 (1H,
d, J 10.1 Hz,eCH2), 4.26e4.10 (5H, m,eCH2e), 3.92 (1H, d, J 12.9 Hz,
eCH2e), 3.32 (1H, t, J 9.1 Hz, eCH2e), 3.27e3.19 (1H, m, eCH2e),
2.61e2.48 (6H, m, eCH2e, eCHe & eCH), 2.06e1.98 (1H, m,
eCH2e), 1.82e1.71 (2H, m, eCH2e), 1.55e1.45 (1H, m, eCH2e). 13C
NMR (125 MHz, DMSO-d6, 120 C): d 172.7, 165.9, 157.6, 136.7, 135.1,
130.9, 129.2, 125.1, 121.3, 120.1, 117.2, 113.8, 81.0, 72.0, 68.5, 62.4,
45.8, 44.4, 41.6, 33.5, 27.2, 24.4, 19.0. HRMS (ESIþ) m/z¼404.1848
[MþNa]þ found, C23H27NO4Naþ required 404.1838.
4.2.23. Synthesis of macrocycle (21). To a stirred solution of 51
(205 mg, 537 mmol) in CH2Cl2 (313 mL) was added Grubb’s second
generation catalyst (45.0 mg, 53.0 mmol). The solution was sub-
sequently degassed and reﬂuxed at 55 C for 2 h under an ethylene
atmosphere. To this solution was added Grubb’s second generation
catalyst (90.0 mg, 106 mmol), after which the solutionwas degassed
and reﬂuxed at 55 C for 28 h under an argon atmosphere. The
solvent was removed under reduced pressure and the crude
product puriﬁed with ﬂash column chromatography, eluting with
30% EtOAc in hexane to yield the title compound as a brown crys-
talline solid (64.9 mg, 32%). TLC Rf¼0.26 (Hexane/EtOAc 4:6). IR
nmax (neat)/cm1: 2933 w (CeH str), 1722 s (C]O str), 1641 s (C]O
str), 1598 s (C]O str), 1489m (C]C str). 1H NMR (500MHz, DMSO-
d6, 120 C): d¼7.64 (1H, d, J 15.8 Hz, eCHCHe), 7.53 (1H, d, J 7.8 Hz,
ArH), 7.32 (1H, t, J 7.3 Hz, ArH), 7.11e7.06 (2H, m, ArH), 6.98 (1H, t, J
7.3 Hz, ArH), 6.19 (1H, d, J 15.8 Hz, eCHCH-), 6.02 (1H, dt, J 15.8,
6.9 Hz, eCHCHe), 5.01 (1H, s, eCH2), 4.93 (1H, s, eCH2) 4.28e4.16
(4H, m, eCH2e), 4.12e4.07 (1H, m, eCH2e), 3.80e3.74 (1H, m,
eCH2e), 3.50e3.42 (1H, m, eCH2e), 3.41e3.34 (1H, m, eCH2e),2.66e2.56 (3H, m, eCH2e & eCHe), 2.51e2.47 (2H, m, eCH2e),
1.99e1.92 (1H, m, eCH2e), 1.86e1.80 (1H, m, eCH2e), 1.75e1.67
(1H, m, eCH2e), 1.55e1.48 (1H, m, eCH2e). 13C NMR (125 MHz,
DMSO-d6, 120 C): d 172.9, 166.0, 157.8, 143.1, 136.8, 133.7, 130.7,
129.7, 127.7, 125.5, 121.4, 120.8, 115.5, 114.0, 69.0, 64.0, 46.4, 43.7,
41.2, 32.3, 31.2, 26.2, 23.0. HRMS (ESIþ) m/z¼382.2018 [MþH]þ
found, C23H28NO4þ required 382.2018.
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